Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib

Tyrosine kinase inhibitors (TKIs) have considerably improved the survival of chronic myelogenous leukemia (CML) patients, especially those in chronic phase (CP). TKIs seem to fully eradicate the disease only in a minority of patients, and the majority need to take these drugs over time, probably indefinitely. The firstCP patients exposed to imatinib mesylate (IM) as first-line therapy have been treated since 2000 in the IRIS (International Randomized Study of Interferon and STI571) study [1, 2].

Source: Experimental Hematology - May 22, 2018 Category: Hematology Authors: Franck Emmanuel Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Ma ël Heiblig, Stéphane Morisset, Gaëlle Fossard, Audrey Bidet, Anna Schmitt, Mohamad Sobh, Sandrine Hayette, François-Xavier Mahon, Stéphanie Dulucq, Gabriel Etienne Source Type: research